TrialNeuro-oncology2024

Encorafenib and binimetinib followed by radiotherapy for patients with BRAFV600-mutant melanoma and brain metastases (E-BRAIN/GEM1802 phase II study).

Iván Márquez-Rodas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.